AMNEAL PHARMACEUTICALS, INC. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $0 for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2024-11-12
- AMNEAL PHARMACEUTICALS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2024-09-30 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2024-06-30 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2024-03-31 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2023-09-30 was $0.00.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month |
|---|---|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |